DelMar Pharmaceuticals Announces Upcoming Investor and Scientific Conference Presentations

VANCOUVER, British Columbia and MENLO PARK, Calif., May 27, 2015 /PRNewswire/ - - DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced that it will be presenting at several upcoming investor and scientific conferences.

Event: Fourth Annual SeeThru Equity Microcap Investor Conference
Presentation with Audio Webcast
Date: Thursday, May 28, 2015
Time: 8:30 a.m. EDT
Location: Convene Grand Central, New York, NY

Event: AACR Advances in Brain Cancer Research Conference
Poster Presentation: Dianhydrogalactitol inhibits the growth of glioma stem and non-stem cultures, including temozolomide-resistant cell lines, in vitro and in vivo
Date: Thursday, May 28, 2015
Time: 1:45-4:30 p.m. EDT
Location: Omni Shoreham Hotel, Washington, DC

Event: Sachs Immuno-Oncology: BD&L and Investment Forum
Presentation and Panel Participation: Pharma-Biotech Business Development & Licensing Panel
Date: Friday, May 29, 2015
Location: Hyatt Chicago Magnificent Mile, Chicago, IL

Event: ASCO Annual Meeting
Poster Presentation: "Phase I/II Study of Dianhydrogalactitol in Patients with Recurrent Malignant Glioma" (abstract no. e19145)
Date: Monday, June 1, 2015
Time: 1:15-4:45 p.m. CDT
Location: McCormick Place, Chicago, IL

A second abstract, entitled, "Activity of Dianhydrogalactitol Alone or with Platinum Drugs Against Non-small Cell Lung Cancer Cell Lines," (abstract no. e19145) will be published online at www.asco.org and jco.ascopubs.org

Event: LD Micro Invitational
Presentation with Audio Webcast
Date: Wednesday, June 3, 2015
Time: 8:30 a.m. PDT / 11:30 a.m. EDT
Location: Luxe Sunset Boulevard, Los Angeles, CA
Live audio webcasts of the SeeThru Equity and LD Micro investor conference presentations will be available by accessing the DelMar's IR Calendar in the Investors section of the Company’s website (www.DelMarPharma.com). The webcast replays will be available approximately two hours after the presentation ends and will be accessible for one month.

DelMar's data presentations from the AACR Advances in Brain Cancer Research and ASCO Annual meeting will be available on the Company's website on the Scientific Publications & Presentations of its website following each respective conference presentation.

About VAL-083

VAL-083 is a "first-in-class", small-molecule chemotherapeutic. In more than 40 Phase 1 and 2 clinical studies sponsored by the U.S. National Cancer Institutes, VAL-083 demonstrated safety and efficacy in treating a number of cancers including lung, brain, cervical, ovarian tumors and leukemia. VAL-083 is approved in China for the treatment of chronic myelogenous leukemia and lung cancer and has received orphan drug designation in Europe and the U.S. for the treatment of gliomas.

As a potential treatment for glioblastoma, VAL-083's mechanism of action appears to be unaffected by the expression of MGMT, a DNA repair enzyme that causes chemotherapy resistance to front-line treatment with Temodar® (temozolomide).

DelMar is currently studying VAL-083 in a multi-center Phase I/II clinical trial for patients with refractory glioblastoma multiforme in accordance with the protocol that has been filed with the U.S. Food and Drug Administration (FDA). Eligible GBM patients must have failed both Avastin® (bevacizumab) and Temodar® (temozolomide) unless either of these therapies was contraindicated. (ClinicalTrials.gov Identifier NCT01478178).

About DelMar Pharmaceuticals, Inc.

DelMar Pharmaceuticals, Inc. was founded to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company's lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.

For further information, please visit http://delmarpharma.com/; or contact DelMar Pharmaceuticals Investor Relations: ir@delmarpharma.com / (604) 629-5989. Follow us on Twitter @DelMarPharma or Facebook.com/delmarpharma. Investor Relations Counsel: Amato & Partners LLC.

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.


SOURCE DelMar Pharmaceuticals, Inc.